Bone Biologics

Bone Biologics is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

About Us

Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development.

  • Currently finalizing pivotal animal studies
  • Clearance to move into human studies in Australia
  • Potential commercialization into $3 billion dollar orthobiologics market pending successful completion of pivotal human studies in U.S
About Us

Market Overview

Bone regeneration is a significant medical challenge impacting millions of people globally.

  • Insufficient bone healing increases the likelihood of systemic medical issues and re-injury
  • The issue is becoming more pronounced as the world population continues to age and become more susceptible to bone injuries.

The orthobiologics industry with its technology advancements will benefit patients and health systems through better outcomes, reduced surgical time, faster healing, and reduced costs.

With an aging population, musculoskeletal diseases are becoming a greater burden as the cost of treating long-term pain and disability increases. Musculoskeletal disease exceeds cancer by 6x.

Source: National Health Interview Survey

Bone Biologics Corp. Advantages

Opportunity

  • 3 billion global market opportunity in spine fusion
  • Additional indications in trauma and osteoporosis

Business

  • A lean, virtual business model with leading
  • strategic partners, vendors, and contractors

Technology

  • Strong technology discovered at UCLA
  • Proprietary product platform with strong IP

Regulatory Path

  • A device/drug combo with device on lead
  • Following medical device PMA tract to FDA approval

Pre-Clinical Data

  • Pre-clinical studies have shown increases in
  • fusion and quantity of bone

Management Team

Jeff Frelick

Chief Executive Officer | President

Jeff Frelick

Jeffrey Frelick assumed the CEO and President role in June 2019. Previously he served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.

Deina Walsh

Chief Financial Officer

Deina Walsh was appointed CFO of Bone Biologics in October 2014. Walsh is a certified public accountant and owner/founder of DHW CPA, PLLC a Public Companies Accounting Oversight Board (PCAOB) registered firm since 2014. Prior to forming her firm, Walsh spent 13 years at a public accounting firm where she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the Sarbanes-Oxley Act. Her experience includes work with start-up companies and well-established operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities. Walsh earned an A.S. in Business Administration from Monroe Community College and a B.S. in Accounting from the State University of New York at Brockport.

Scott D. Boden, MD

Chief Medical Advisor

Scott Boden

Dr. Scott Boden is the Chief Medical Advisor of Bone Biologics. He is also a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. Dr. Boden also serves as the Clinical Director of the Whitesides Orthopaedic Research Laboratory and has received many awards, authored over 175 peer-reviewed articles on spine and basic science topics, as well as 30 chapters and 7 textbooks. He is Co-Editor of Seminars in Spine Surgery, a Deputy Editor of SPINE, and a reviewer for The Journal of Bone and Joint Surgery, The Journal of Bone and Mineral Research, and the European Spine Journal. Dr. Boden served as President and Secretary and President of the American Orthopaedic Association. He received his B.A. and M.D. from the University of Pennsylvania and completed an Orthopaedic Residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.

Board of Directors

Don R. Hankey, Chairman

CEO/Chairman, Hankey Group

Don Hankey

Mr. Hankey holds his BA and post-graduate work from the University of Southern California. At age 27, Mr. Hankey became Vice President of a major investment banking firm, which would later become part of USB Paine Weber. Mr. Hankey acquired Midway Ford in 1972 and founded Hankey Investment Company in 1982. During the 1980s Mr. Hankey’s organization grew its portfolio and established a foothold in the financial services industry. Mr. Hankey has incorporated technology into every aspect of the Hankey Group of companies improving efficiencies and outcomes. Mr. Hankey has been the manager of Hankey Capital, LLC, since its formation in 2002.

John Booth, Director

CEO, Spineology

John Booth

Mr. Booth has been CEO of Spineology Inc. since 2004 and has been a board member since its inception in 1998. He held various executive level positions at Phillips Plastics Corporation, most recently serving as CEO from 2001 to 2002. He was CEO of Microvena Corporation, a cardiovascular device subsidiary of Phillips, from 1999 to 2001 and CEO of Phillips Origen Group Division from 1998 to 1999. Prior to Phillips, Booth was President and CEO of INCSTAR Corporation, a publicly held medical technology company involved in in-vitro diagnostics. He has held various positions in both financial and general management in the medical technology industry since 1981. Booth earned a B.S. in accounting from Villanova University and an M.B.A. from Seton Hall University.

Bret Hankey, Director

President, Hankey Group

Bret Hankey

Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board. Since 2000, Mr. Hankey has served in various capacities within the Hankey Group where he currently serves as President and is a member of the board of directors on all seven operating companies specializing primarily in the automotive, finance, technology, real estate and insurance industries.

Bruce Stroever, Director

Former CEO, Musculoskeletal Transplant Foundation

Bruce Stroever

Mr. Stroever has forty years of product development and general management experience in the medical device and orthobiologics fields. Mr. Stroever joined MTF in late 1988 as General Manager and retired in mid-2018 from his position as the President and Chief Executive Officer of MTF. He served as MTF’s President since his appointment in 1992 and as Chief Executive Officer since 1996. Under Mr. Stroever’s leadership, MTF grew to be the largest tissue bank in the world providing over 500,000 grafts per year with revenues over $400 million. From 1971 to 1988, Mr. Stroever held several positions with Ethicon, Inc., a Johnson & Johnson, Inc. subsidiary. Mr. Stroever currently serves on the advisory board for the New Jersey Organ and Tissue Sharing Network. He was elected to the Board of Governors of the American Association of Tissue Banks for a three year term in 1999 and subsequently in 2012. He was a founding member of the Tissue Policy Group subsidiary of the AATB and served as its Chairman for two terms. Mr. Stroever served as the Chairman of the Bone Biologics Board of Directors from 2012 through mid-2018. Mr. Stroever received his B.E. in Mechanical/Chemical Engineering from Stevens Institute of Technology in 1972 and a Masters of Science in Bioengineering from Columbia University in 1977.

Stephen R. La Neve, Director

Former CEO/President, Bone Biologics

Stephen La Neve

Mr. La Neve brings 30 years of health care experience and leadership to Bone Biologics. Previously Mr. La Neve was CEO of Bone Biologics, Life Science Enterprises, and ETEX Corp. while holding divisional president roles at Medtronic and Becton Dickinson. He holds a B.S. in Health Planning from Penn State University and an MBA West Chester University.